-transparent.png){kind=logo}
This study involved the administration of amonafide intravenously 300 mg/m2 daily times five days every three weeks to 16 refractory and relapsed myeloma patients. Doses were escalated to toxicity. These doses caused severe thrombocytopenia and granulocytopenia in seven patients. No responses were seen in this heavily pretreated group of patients.
Related Publications
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
February 1998,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
February 1993,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
November 1991,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
January 1993,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
February 2002,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
January 1994,
Cancer investigation,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
January 1994,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
November 1991,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
January 1994,
Investigational new drugs,
K H Hanson, and
J Crowley, and
S E Salmon, and
M Keppen, and
T J Braun, and
J D Bonnet
February 1990,
Investigational new drugs,
